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Non–ST-Segment Elevation
Myocardial Infarction
Revascularization for Everyone?*
Robbert J. de Winter, MD, PHD,
Jan G. P. Tijssen, PHD
Amsterdam, the Netherlands
Patients with acute coronary syndrome, the sudden clinical
manifestation of atherosclerotic heart disease, may present
as ST-segment elevation myocardial infarction (STEMI),
non–ST-segment elevation myocardial infarction (NSTEMI),
or unstable angina. Patients with STEMI typically have
complete and persistent occlusion of a large epicardial coronary
artery with a large area of myocardium at risk and severe chest
pain, whereas patients with NSTEMI may present with a
more heterogeneous condition: varying degrees of reduction of
coronary flow but without complete coronary occlusion in
combination with distal embolization of thrombotic material
and accompanying coronary spasm. Atherosclerotic changes in
the vessel wall, extent of calcification, the degree of plaque
rupture and subsequent intracoronary thrombus formation
may vary considerably in NSTEMI patients. In addition,
myocardial necrosis (and troponin elevation) may occur in
the absence of coronary thrombosis but in the presence of
stable but diffuse severe coronary disease and clinical con-
ditions that increase myocardial demand, such as acute
decompensated heart failure or tachyarrhythmias, such as
rapid atrial fibrillation. Patients with NSTEMI have lower
30-day mortality than STEMI patients, but at 1 year, this
difference in mortality is no longer present.
See page 893
Current STEMI guidelines recommend urgent angiog-
raphy followed by immediate mechanical opening of the
infarct-related coronary artery to restore coronary flow
(reperfusion therapy), a strategy that has been shown to
reduce mortality. In NSTEMI patients, however, there has
been continued debate over the last 10 years whether
“immediate,” “urgent,” or “early” angiography and revascu-
*Editorials published in JACC: Cardiovascular Interventions reflect the views of the
uthors and do not necessarily represent the views of JACC: Cardiovascular Interven-
ions or the American College of Cardiology.
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or “selective invasive” approach.
Current NSTEMI guidelines recommend the assessment
of ischemic risk and bleeding risk using validated risk scores
in each individual patient to decide on pharmacological and
invasive management (1,2). The guidelines recommend
urgent or immediate transfer to the catheterization labora-
tory for patients with ongoing signs and symptoms of
ischemia and for patients with hemodynamic or electric
instability. An early invasive management in high-risk
patients with non–ST-segment elevation acute coronary
syndrome (NSTE-ACS) is recommended, with high-risk
features, including evidence of myocardial necrosis resulting
in troponin elevations, ongoing myocardial ischemia with
dynamic ST-segment changes on the electrocardiogram, the
presence of diabetes mellitus, and a history of a recent
percutaneous coronary intervention (PCI) or coronary artery
bypass graft (CABG). Although women and elderly pa-
tients are under-represented in the randomized controlled
trials (RCT) and these patients may be at higher risk of
procedural complications, available evidence suggest that
after appropriate risk stratification, the benefit of an early
invasive management extends to all subgroups. Importantly,
with advanced age, the absolute risk of death or MI is
increased and potential absolute risk reduction from early
revascularization in elderly patients may be substantial (1,2).
Meta-analyses of the RCT comparing an early invasive
management strategy with a more conservative or selective
invasive management have shown that an early invasive
management reduced the composite of death or MI, in
particular in patients with high ischemic risk scores (3,4). In
a recent analysis, including FIR (FRISC-II [Fragmin and
Fast Revascularization During Instability in Coronary Ar-
tery Disease], ICTUS [Invasive Versus Conservative Treat-
ment in Unstable Coronary Syndromes], and RITA 3
[Randomized Intervention Trial of Unstable Angina]), of a
large per patient combined dataset, comprising over 5,000
patients, 5-year incidence of the combined endpoint death
or nonfatal MI was reduced by an early invasive manage-
ment (5). Yet, in contrast to the evidence from STEMI
trials, neither in the meta-analyses of all RCT nor in the
FIR analysis has a statistically significant reduction in
long-term mortality been demonstrated to be associated
with early invasive management. In the analysis by Mehta et
al. (3), combining the results of 7 trials with varying time
intervals of follow-up, mortality associated with a routine
invasive management at the end of follow-up was 5.5%
versus 6.0% associated with a conservative management
(odds ratio [OR]: 0.92; 95% confidence interval [CI]: 0.77
to 1.09; p  0.34). In the FIR analysis, comprising 5,467
patients with 5-year outcomes, a trend toward a reduction in
cardiovascular deaths and in all deaths was shown in favor of
an early invasive management compared with a more
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904selective invasive management (cardiovascular death: RI
6.8% vs. SI 8.1%; hazard ratio [HR]: 0.83, 95% CI: 0.68 to
1.01; p  0.068) (all deaths: routine invasive [RI] 10.6% vs.
elective invasive [SI] 11.7%; HR: 0.90, 95% CI: 0.77 to
.05). For the combined endpoint, there were 2.0% to 3.8%
bsolute reductions in cardiovascular death or MI in the
ow- and intermediate-risk groups and an 11.1% absolute
isk reduction in highest-risk patients (5).
In this issue of JACC: Cardiovascular Interventions,
Puymirat et al. (6) provide data for a large cohort of
NSTEMI patients from the FAST-MI (French Registry of
Acute Coronary Syndrome). During 1 month in 2005,
3,670 all-comers ACS patients were prospectively enrolled
in 223 centers within 48 h after symptom onset, including
1,645 NSTEMI patients (45%). Invasive management
strategy (IS) was defined as angiography with or without
revascularization, and conservatively managed patients (CS)
did not undergo angiography and received only medical
therapy. Management choice was at the discretion of the
treating physician, resulting in 80% of patients managed
invasively. Patients in the IS group were younger (67  12
ears vs. 80  11 years), less often women (29% vs. 51%),
nd had a lower GRACE (Global Registry of Acute
oronary Events) risk scores (137  36 vs. 178  34)
ompared with patients treated with CS. In-hospital mor-
ality was significantly more frequent in patients with CS
han with IS (13.1% vs. 2.0%). Use of IS was statistically
ignificantly associated with a lower 3-year all-cause and
ardiovascular mortality (17% vs. 60% and 8% vs. 36%).
fter propensity score matching (181 patients per group) to
djust for differences in baseline risk, 3-year survival was
ignificantly better in patients treated with an invasive
trategy. The study has several important strengths and adds
o our knowledge from RCT and meta-analyses. First,
ll-comers patients were included in a real-life clinical
nvironment. Second, the study excluded patients with
atrogenic or procedure-related MI, as well as patients in
hom another diagnosis was favored over ACS and patients
ith negative cardiac necrosis markers. Third, the registry
as a prospective registry, patients were followed up for 3
ears, and importantly, follow-up was 99% complete at 1
ear and 97% at 3 years. In addition, bleeding complications
nd need for blood transfusions were carefully recorded.
egistry data without scheduled follow-up visits and for-
alized event monitoring may be limited by under-
eporting of ischemic events and (repeat) revascularization
rocedures, but vital status and cause of death is likely to be
eliable and complete in this study. Can we now conclude
hat an early invasive strategy in all NSTEMI patients
educes mortality and restrict a conservative strategy only to
atients who are considered low risk, too high risk to
ndergo a procedure, or who are unwilling to undergo
ngiography? pPerhaps not. In a post hoc analysis of the SYNERGY
Superior Yield of the New Strategy of Enoxaparin, Revas-
ularization, and glycoprotein IIb/IIIa Inhibitors) trial,
ne-third of patients with NSTE-ACS and significant
oronary disease on early angiography were managed with-
ut in-hospital revascularization. The strongest indepen-
ent predictors of conservative medical management versus
ny intervention were prior CABG, lower body weight, and
-vessel disease, clearly delineating increased baseline risk.
ith conservative medical management, the cumulative
isk of 1-year mortality after discharge increased during the
rst 90 days and thereafter remained higher at 7.7%
ompared with that seen in patients treated with PCI
3.6%) or CABG (6.2%) (7). This association between
ngiography and a reduction in mortality in non-STE-ACS
atients has also been consistently shown in retrospective
ohort studies (8). Typically, a relative risk reduction of 50%
n cardiovascular death or all-cause death was associated
ith early angiography, but baseline risk was also signifi-
antly higher in conservatively managed patients. In registry
ohort studies, where the decision to perform angiography is
ot formally defined in the protocol, strategy is dependent
n the availability of a catheterization laboratory, hospital
rotocols, regional practice, and individual physician pref-
rence. Thus, if angiography is the default strategy in
atients with NSTEMI, the decision to refrain from an-
iography is likely reached on the basis of actual or antici-
ated individual patient risk associated with an invasive
rocedure, such as severe renal insufficiency, severe chronic
eart failure, pulmonary disease, absence of revasculariza-
ion options in patients with recent angiographic data, or
railty associated with advanced age. The clinical informa-
ion available to the treating physician will not be com-
letely captured in the variables defined in the registry
eport form. Analytical techniques to eliminate bias due to
onfounding, such as propensity score analyses may not be
ble to adjust for important prognostic indicators associated
ith the decision not to perform angiography. To illustrate
his, Hirsch et al. (9) recently performed a “retrospective”
nalysis of patients in the ICTUS study and demonstrated a
1% reduction in mortality associated with revasculariza-
ion, whereas in the same dataset, prospective randomiza-
ion to an invasive management strategy was not shown to
e beneficial. Stukel et al. (10) have previously shown that
he observational association of invasive practice and out-
ome in acute MI patients was highly dependent on the
tatistical methods used. Propensity score adjusted analyses
ill inevitably suffer from residual unmeasured confounders,
hereas other techniques, such as instrumental variable anal-
ses designed to control for hidden bias, will not. Thus, as
uymirat et al. (6) mentioned, the results of their analyses are
ntriguing but can only be considered indicative. The use of
aplan-Meier curves in Figure 1 of the Puymirat et al. (6)
aper suggests that the management strategy (IS or CS) was
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905chosen at hospital admission (time 0 in the Kaplan-Meier
curve). However, the CS group consisted of all patients who
did not undergo coronary angiogram during the initial
hospitalization, including patients who died early, that is,
before they could be catheterized. This analytical approach
biases survival in the IS group.
Finally, the results from the RCT represent clinical
practice from the era before 2005. In addition, Puymirat et
al. (6) enrolled patients in 2005, and both the diagnostic and
therapeutic treatment options for ACS patients have
evolved dramatically since then. The use of the new P2Y12
antagonists (e.g., prasugrel and ticagrelor) was associated
with an approximately 20% relative reduction in ischemic
events in ACS patients and improved prognoses in STEMI
and NSTEMI patients alike, both with an invasive man-
agement and with medical management. Bleeding was also
reduced using Fondaparinux or bivalirudin (1,2). Since
2005, we have better PCI techniques and better coronary
stents with improved deliverability, lower restenosis risk,
and lower stent thrombosis risk. Access site–related bleed-
ing complications decrease using the radial approach. With
better tools for risk stratification, we are able to identify
ACS patients who may benefit most from early angiography
and revascularization. Physicians are struggling with the
clinical implications of the high-sensitivity troponin assays,
which allow us to detect even the smallest changes in cardiac
troponins, which inevitably results in a larger number of
patients with ACS who, according to the guidelines, should
be managed invasively.
In summary, early intervention is recommended in high-
risk ACS patients and implemented in most centers. Al-
though mortality reduction may be modest, an invasive
strategy significantly reduced death or MI. Early angiogra-
phy is safe and practical in most patients. Yet, perhaps it is
time for a new, large, randomized clinical trial for
intermediate-risk NSTE-ACS patients, comparing an early
invasive strategy with a selective invasive strategy, and using
high-sensitive troponin measurements and risk stratification
tools, the latest interventional modalities, and optimized
pharmacological standards of care. The outcome of such a
trial, which could enroll a representative number of elderly
and female patients to mirror our everyday clinical patient
population, might surprise us.Reprint requests and correspondence: Prof. Robert J. de Winter,
Department of Cardiology, B2-137 Academic Medical Center,
Meibergdreef 9, 1105 AZ Amsterdam, the Netherlands. E-mail:
r.j.dewinter@amc.uva.nl.
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